Ernexa Therapeutics Inc. (ERNA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ernexa Therapeutics Inc. (formerly Eterna Therapeutics Inc.) on March 26, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "ERNA". The report details a corporate name change effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Corporate Name Change: Effective March 26, 2025, the company changed its name from Eterna Therapeutics Inc. to Ernexa Therapeutics Inc.
- Charter Amendment: The company filed an amendment to its Restated Certificate of Incorporation with the Delaware Secretary of State to reflect the new name.
- Bylaws Update: The company adopted amended and restated bylaws solely to reflect the name change.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural announcement of the name change.
Key Facts for Investor Verification
- Verify the effective date of the name change (March 26, 2025) and confirm the new ticker symbol remains "ERNA" on Nasdaq.
- Review the attached Exhibit 3.1 (Certificate of Amendment) and Exhibit 3.2 (Amended Bylaws) to confirm the legal documentation of the name change.
- Confirm that the name change does not signal a strategic pivot or operational shift beyond the rebranding, as no such details are provided in this filing.